Treatment of neurodegenerative disorders through the blood-brain barrier using nanocarriers

Neurodegenerative diseases refer to disorders of the central nervous system (CNS) that are caused by neuronal degradations, dysfunctions, or death. Alzheimer's disease, Parkinson's disease, and Huntington's disease (APHD) are regarded as the three major neurodegenerative diseases. The...

Full description

Saved in:
Bibliographic Details
Published in:Nanoscale 2018-09, Vol.1 (36), p.16962-16983
Main Authors: Poovaiah, N, Davoudi, Z, Peng, H, Schlichtmann, B, Mallapragada, S, Narasimhan, B, Wang, Q
Format: Article
Language:English
Subjects:
Alzheimer's disease
Blood-Brain Barrier
Brain
Central nervous system
Disorders
Drug Delivery Systems
Emulsions - therapeutic use
Humans
Liposomes
Liposomes - therapeutic use
Nanoemulsions
Nanomaterials
Nanomedicine
Nanoparticles
Nanoparticles - therapeutic use
Neurodegenerative Diseases - drug therapy
Neurological diseases
Parkinson's disease
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Neurodegenerative diseases refer to disorders of the central nervous system (CNS) that are caused by neuronal degradations, dysfunctions, or death. Alzheimer's disease, Parkinson's disease, and Huntington's disease (APHD) are regarded as the three major neurodegenerative diseases. There is a vast body of literature on the causes and treatments of these neurodegenerative diseases. However, the main obstacle in developing an effective treatment strategy is the permeability of the treatment components at the blood-brain barrier (BBB). Several strategies have been developed to improve this obstruction. For example, nanomaterials facilitate drug delivery to the BBB due to their size. They have been used widely in nanomedicine and as nanoprobes for diagnosis purposes among others in neuroscience. Nanomaterials in different forms, such as nanoparticles, nanoemulsions, solid lipid nanoparticles (SLN), and liposomes, have been used to treat neurodegenerative diseases. This review will cover the basic concepts and applications of nanomaterials in the therapy of APHD. This review highlights the recent advancements in the preparations and applications of nanocarriers in the treatment of neurodegenerative disorders through the blood-brain barrier.
ISSN:2040-3364
2040-3372
DOI:10.1039/c8nr04073g